var bibbase_data = {"data":"\"Loading..\"\n\n
\n\n \n\n \n\n \n \n\n \n\n \n \n\n \n\n \n
\n generated by\n \n \"bibbase.org\"\n\n \n
\n \n\n
\n\n \n\n\n
\n\n Excellent! Next you can\n create a new website with this list, or\n embed it in an existing web page by copying & pasting\n any of the following snippets.\n\n
\n JavaScript\n (easiest)\n
\n \n <script src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fgroups%2F4789160%2Fitems%3Fkey%3D2rWN9VqdJDeUg6R6872EsU6o%26format%3Dbibtex%26limit%3D100&jsonp=1&jsonp=1\"></script>\n \n
\n\n PHP\n
\n \n <?php\n $contents = file_get_contents(\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fgroups%2F4789160%2Fitems%3Fkey%3D2rWN9VqdJDeUg6R6872EsU6o%26format%3Dbibtex%26limit%3D100&jsonp=1\");\n print_r($contents);\n ?>\n \n
\n\n iFrame\n (not recommended)\n
\n \n <iframe src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fgroups%2F4789160%2Fitems%3Fkey%3D2rWN9VqdJDeUg6R6872EsU6o%26format%3Dbibtex%26limit%3D100&jsonp=1\"></iframe>\n \n
\n\n

\n For more details see the documention.\n

\n
\n
\n\n
\n\n This is a preview! To use this list on your own web site\n or create a new web site from it,\n create a free account. The file will be added\n and you will be able to edit it in the File Manager.\n We will show you instructions once you've created your account.\n
\n\n
\n\n

To the site owner:

\n\n

Action required! Mendeley is changing its\n API. In order to keep using Mendeley with BibBase past April\n 14th, you need to:\n

    \n
  1. renew the authorization for BibBase on Mendeley, and
  2. \n
  3. update the BibBase URL\n in your page the same way you did when you initially set up\n this page.\n
  4. \n
\n

\n\n

\n \n \n Fix it now\n

\n
\n\n
\n\n\n
\n \n \n
\n
\n  \n 2021\n \n \n (3)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update.\n \n \n \n \n\n\n \n Fischer, B.; Robinson, T.; Bullen, C.; Curran, V.; Jutras-Aswad, D.; Medina-Mora, M. E.; Pacula, R. L.; Rehm, J.; Room, R.; Brink, W. v. d.; and Hall, W.\n\n\n \n\n\n\n International Journal of Drug Policy,103381. August 2021.\n \n\n\n\n
\n\n\n\n \n \n \"Lower-RiskPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@article{fischer_lower-risk_2021,\n\ttitle = {Lower-{Risk} {Cannabis} {Use} {Guidelines} ({LRCUG}) for reducing health harms from non-medical cannabis use: {A} comprehensive evidence and recommendations update},\n\tissn = {0955-3959},\n\tshorttitle = {Lower-{Risk} {Cannabis} {Use} {Guidelines} ({LRCUG}) for reducing health harms from non-medical cannabis use},\n\turl = {https://www.sciencedirect.com/science/article/pii/S0955395921002863},\n\tdoi = {10.1016/j.drugpo.2021.103381},\n\tabstract = {Background\nCannabis use is common, especially among young people, and is associated with risks for various health harms. Some jurisdictions have recently moved to legalization/regulation pursuing public health goals. Evidence-based ‘Lower Risk Cannabis Use Guidelines’ (LRCUG) and recommendations were previously developed to reduce modifiable risk factors of cannabis-related adverse health outcomes; related evidence has evolved substantially since. We aimed to review new scientific evidence and to develop comprehensively up-to-date LRCUG, including their recommendations, on this evidence basis.\nMethods\nTargeted searches for literature (since 2016) on main risk factors for cannabis-related adverse health outcomes modifiable by the user-individual were conducted. Topical areas were informed by previous LRCUG content and expanded upon current evidence. Searches preferentially focused on systematic reviews, supplemented by key individual studies. The review results were evidence-graded, topically organized and narratively summarized; recommendations were developed through an iterative scientific expert consensus development process.\nResults\nA substantial body of modifiable risk factors for cannabis use-related health harms were identified with varying evidence quality. Twelve substantive recommendation clusters and three precautionary statements were developed. In general, current evidence suggests that individuals can substantially reduce their risk for adverse health outcomes if they delay the onset of cannabis use until after adolescence, avoid the use of high-potency (THC) cannabis products and high-frequency/-intensity of use, and refrain from smoking-routes for administration. While young people are particularly vulnerable to cannabis-related harms, other sub-groups (e.g., pregnant women, drivers, older adults, those with co-morbidities) are advised to exercise particular caution with use-related risks. Legal/regulated cannabis products should be used where possible.\nConclusions\nCannabis use can result in adverse health outcomes, mostly among sub-groups with higher-risk use. Reducing the risk factors identified can help to reduce health harms from use. The LRCUG offer one targeted intervention component within a comprehensive public health approach for cannabis use. They require effective audience-tailoring and dissemination, regular updating as new evidence become available, and should be evaluated for their impact.},\n\tlanguage = {en},\n\turldate = {2021-08-31},\n\tjournal = {International Journal of Drug Policy},\n\tauthor = {Fischer, Benedikt and Robinson, Tessa and Bullen, Chris and Curran, Valerie and Jutras-Aswad, Didier and Medina-Mora, Maria Elena and Pacula, Rosalie Liccardo and Rehm, Jürgen and Room, Robin and Brink, Wim van den and Hall, Wayne},\n\tmonth = aug,\n\tyear = {2021},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {103381},\n}\n\n
\n
\n\n\n
\n Background Cannabis use is common, especially among young people, and is associated with risks for various health harms. Some jurisdictions have recently moved to legalization/regulation pursuing public health goals. Evidence-based ‘Lower Risk Cannabis Use Guidelines’ (LRCUG) and recommendations were previously developed to reduce modifiable risk factors of cannabis-related adverse health outcomes; related evidence has evolved substantially since. We aimed to review new scientific evidence and to develop comprehensively up-to-date LRCUG, including their recommendations, on this evidence basis. Methods Targeted searches for literature (since 2016) on main risk factors for cannabis-related adverse health outcomes modifiable by the user-individual were conducted. Topical areas were informed by previous LRCUG content and expanded upon current evidence. Searches preferentially focused on systematic reviews, supplemented by key individual studies. The review results were evidence-graded, topically organized and narratively summarized; recommendations were developed through an iterative scientific expert consensus development process. Results A substantial body of modifiable risk factors for cannabis use-related health harms were identified with varying evidence quality. Twelve substantive recommendation clusters and three precautionary statements were developed. In general, current evidence suggests that individuals can substantially reduce their risk for adverse health outcomes if they delay the onset of cannabis use until after adolescence, avoid the use of high-potency (THC) cannabis products and high-frequency/-intensity of use, and refrain from smoking-routes for administration. While young people are particularly vulnerable to cannabis-related harms, other sub-groups (e.g., pregnant women, drivers, older adults, those with co-morbidities) are advised to exercise particular caution with use-related risks. Legal/regulated cannabis products should be used where possible. Conclusions Cannabis use can result in adverse health outcomes, mostly among sub-groups with higher-risk use. Reducing the risk factors identified can help to reduce health harms from use. The LRCUG offer one targeted intervention component within a comprehensive public health approach for cannabis use. They require effective audience-tailoring and dissemination, regular updating as new evidence become available, and should be evaluated for their impact.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Sevrage d'alcool et prévention des rechutes.\n \n \n \n \n\n\n \n INESSS\n\n\n \n\n\n\n 2021.\n \n\n\n\n
\n\n\n\n \n \n \"SevragePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{inesss_sevrage_2021,\n\ttitle = {Sevrage d'alcool et prévention des rechutes},\n\turl = {https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Usage_optimal/INESSS_GUO_Sevrage_rechute_FR.pdf},\n\turldate = {2021-11-23},\n\tauthor = {{INESSS}},\n\tyear = {2021},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Trouble lié à l'usage d'opioïdes (TUO).\n \n \n \n \n\n\n \n INESSS\n\n\n \n\n\n\n 2021.\n \n\n\n\n
\n\n\n\n \n \n \"TroublePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{inesss_trouble_2021,\n\ttitle = {Trouble lié à l'usage d'opioïdes ({TUO})},\n\turl = {https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/GUO_TUO_FR.pdf},\n\turldate = {2021-11-23},\n\tauthor = {{INESSS}},\n\tyear = {2021},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2020\n \n \n (11)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Le cadre thérapeutique en contexte de pandémie : vers un nouvel équilibre.\n \n \n \n \n\n\n \n Magny, A.\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"LePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n
@misc{magny_cadre_2020,\n\ttitle = {Le cadre thérapeutique en contexte de pandémie : vers un nouvel équilibre},\n\turl = {https://www.ordrepsy.qc.ca/-/le-cadre-therapeutique-en-contexte-de-pandemie-vers-un-nouvel-equilibre/1.5},\n\turldate = {2022-05-03},\n\tjournal = {Ordre des Psychologues du Québec},\n\tauthor = {Magny, André-Anne},\n\tyear = {2020},\n\tkeywords = {COVID-19, Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Le traitement du trouble lié à l'utilisation d'opioïdes (TUO) : lignes directrices.\n \n \n \n \n\n\n \n Collège des médecins du Québec; Ordre des infirmières et infirmiers du Québec; and Ordre des pharmaciens du Québec\n\n\n \n\n\n\n March 2020.\n \n\n\n\n
\n\n\n\n \n \n \"LePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 13 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{college_des_medecins_du_quebec_traitement_2020,\n\ttitle = {Le traitement du trouble lié à l'utilisation d'opioïdes ({TUO}) : lignes directrices},\n\turl = {http://www.cmq.org/publications-pdf/p-1-2020-03-20-fr-le-traitement-du-trouble-lie-a-l-utilisation-d-opioides-tuo.pdf},\n\tlanguage = {fr},\n\turldate = {2020-05-06},\n\tauthor = {{Collège des médecins du Québec} and {Ordre des infirmières et infirmiers du Québec} and {Ordre des pharmaciens du Québec}},\n\tmonth = mar,\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Médication et autres approches pour soutenir la distanciation physique des personnes utilisatrices de substances : guide pratique national.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"MédicationPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_medication_2020,\n\ttitle = {Médication et autres approches pour soutenir la distanciation physique des personnes utilisatrices de substances : guide pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/08/Me%CC%81dication-et-autres-approches-pour-soutenir-la-distanciation-physique-des-personnes-utilisatrices-de-substances-31072020.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n La pharmacothérapie de remplacement des substances psychoactives dans le contexte de pandémie de COVID-19 au Québec : guide clinique à l'intention des prescripteurs.\n \n \n \n \n\n\n \n Goyer, M.; Hudon, K; Plessis-Bélair, M.; and Ferguson, Y\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"LaPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 5 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{goyer_pharmacotherapie_2020,\n\ttitle = {La pharmacothérapie de remplacement des substances psychoactives dans le contexte de pandémie de {COVID}-19 au {Québec} : guide clinique à l'intention des prescripteurs},\n\turl = {https://www.bibliothequeduchum.ca/projets/tc/documents/Guide%20clinique%20Pharmacothe%CC%81rapie%20COVID_9-6-2020.pdf},\n\turldate = {2020-06-29},\n\tpublisher = {Institut universitaire sur les dépendances},\n\tauthor = {Goyer, ME and Hudon, K and Plessis-Bélair, MC and Ferguson, Y},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Medications and other clinical approaches to support physical distancing for people who use substances during the COVID-19 pandemic.\n \n \n \n \n\n\n \n Brar, R; Bruneau, J; Butt, P; Goyer, M.; Lim, R; Poulin, G; Sereda, A; Robinson, S; and Wood, E\n\n\n \n\n\n\n June 2020.\n \n\n\n\n
\n\n\n\n \n \n \"MedicationsPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{brar_medications_2020,\n\ttitle = {Medications and other clinical approaches to support physical distancing for people who use substances during the {COVID}-19 pandemic},\n\turl = {https://www.crismquebecatlantic.ca/fr/medications-and-other-clinical-approaches-to-support-physical-distancing-for-people-who-use-substances-during-the-covid-19-pandemic/},\n\tlanguage = {Anglais},\n\turldate = {2020-06-29},\n\tpublisher = {Canadian Research Initiative in Substance Misuse},\n\tauthor = {Brar, R and Bruneau, J and Butt, P and Goyer, ME and Lim, R and Poulin, G and Sereda, A and Robinson, S and Wood, E},\n\tmonth = jun,\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Télémédecine pour le traitement des troubles liés à l'usage de substances psychoactives : guide pratique national.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"TélémédecinePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_telemedecine_2020,\n\ttitle = {Télémédecine pour le traitement des troubles liés à l'usage de substances psychoactives : guide pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/08/COVID19-LDPN-Telemedecine-01072020.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Stratégies pour réduire la transmission du SRASCoV-2 dans les centres de réadaptation en dépendance et d’hébergement : guide pratique national.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"StratégiesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_strategies_2020,\n\ttitle = {Stratégies pour réduire la transmission du {SRASCoV}-2 dans les centres de réadaptation en dépendance et d’hébergement : guide pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/09/Strat%C3%A9gies-pour-r%C3%A9duire-la-transmission-du-SRAS-CoV-2-dans-les-centres-de-r%C3%A9adaptation-en-d%C3%A9pendance-et-d%E2%80%99h%C3%A9bergement-20072020.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Soutenir les personnes utilisatrices de substances dans un milieu de soins de courte durée pendant la pandémie de la COVID‑19 : guide pratique national.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"SoutenirPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_soutenir_2020,\n\ttitle = {Soutenir les personnes utilisatrices de substances dans un milieu de soins de courte durée pendant la pandémie de la {COVID}‑19 : guide pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/08/Soutenir-les-PUS-dans-un-milieu-de-soins-de-courte-dur%C3%A9e-31072020.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Sécurité des travailleurs en prévention et réduction des risques durant la pandémie de la COVID‑19 : guide pratique national.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"SécuritéPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 5 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_securite_2020,\n\ttitle = {Sécurité des travailleurs en prévention et réduction des risques durant la pandémie de la {COVID}‑19 : guide pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/09/S%C3%A9curit%C3%A9-des-travailleurs-en-pr%C3%A9vention-et-r%C3%A9duction-des-risques-durant-la-pand%C3%A9mie-de-la-COVID-19-31072020.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n Journal of Addiction Medicine, 14(3S): 1–72. June 2020.\n \n\n\n\n
\n\n\n\n \n \n \"ThePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@article{noauthor_asam_2020,\n\ttitle = {The {ASAM} {Clinical} {Practice} {Guideline} on {Alcohol} {Withdrawal} {Management}},\n\tvolume = {14},\n\tissn = {1932-0620},\n\turl = {https://journals.lww.com/journaladdictionmedicine/Fulltext/2020/06001/The_ASAM_Clinical_Practice_Guideline_on_Alcohol.1.aspx},\n\tdoi = {10.1097/ADM.0000000000000668},\n\tlanguage = {en-US},\n\tnumber = {3S},\n\turldate = {2020-09-29},\n\tjournal = {Journal of Addiction Medicine},\n\tmonth = jun,\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {1--72},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Soutenir les personnes utilisatrices de substances dans les centres d’accueil pendant la pandémie de la COVID‑19 : guide pratique national.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance\n\n\n \n\n\n\n 2020.\n \n\n\n\n
\n\n\n\n \n \n \"SoutenirPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_soutenir_2020-1,\n\ttitle = {Soutenir les personnes utilisatrices de substances dans les centres d’accueil pendant la pandémie de la {COVID}‑19 : guide pratique national},\n\turl = {https://crism.ca/wp-content/uploads/2020/08/Soutenir-les-personnes-utilisatrices-de-substances-dans-les-centres-d%E2%80%99accueil-pendant-la-pand%C3%A9mie-de-la-COVID-19-14072020.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{Initiative canadienne de recherche en abus de substance}},\n\tyear = {2020},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2019\n \n \n (7)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Guide de pratique pour la thérapie des schémas.\n \n \n \n \n\n\n \n Gauthier, C.; Chaloult, G.; Goulet, J.; and Ngô, T.\n\n\n \n\n\n\n Technical Report 2019.\n \n\n\n\n
\n\n\n\n \n \n \"GuidePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@techreport{gauthier_guide_2019,\n\ttitle = {Guide de pratique pour la thérapie des schémas},\n\turl = {https://tccmontreal.files.wordpress.com/2019/11/guide-schema-final-1.pdf},\n\turldate = {2022-04-19},\n\tauthor = {Gauthier, C. and Chaloult, G. and Goulet, J. and Ngô, T.L.},\n\tyear = {2019},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Guide d'intervention : Consentement aux soins.\n \n \n \n \n\n\n \n intégré de santé et de services sociaux de l'Outaouais , C.\n\n\n \n\n\n\n 2019.\n \n\n\n\n
\n\n\n\n \n \n \"GuidePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@book{centre_integre_de_sante_et_de_services_sociaux_de_loutaouais_guide_2019,\n\ttitle = {Guide d'intervention : {Consentement} aux soins},\n\tisbn = {ISBN 978-2-550-83652-0},\n\turl = {https://numerique.banq.qc.ca/patrimoine/details/52327/3660036},\n\tlanguage = {fr},\n\turldate = {2022-11-17},\n\tauthor = {Centre intégré de santé et de services sociaux de l'Outaouais},\n\tyear = {2019},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder.\n \n \n \n \n\n\n \n Reus, V. I.; Fochtmann, L. J.; Bukstein, O.; Eyler, A. E.; Hilty, D. M.; Horvitz-Lennon, M.; Mahoney, J.; Pasic, J.; Weaver, M.; Wills, C. D.; McIntyre, J.; Kidd, J.; Yager, J.; and Hong, S.\n\n\n \n\n\n\n Focus (American Psychiatric Publishing), 17(2): 158–162. April 2019.\n \n\n\n\n
\n\n\n\n \n \n \"ThePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@article{reus_american_2019,\n\ttitle = {The {American} {Psychiatric} {Association} {Practice} {Guideline} for the {Pharmacological} {Treatment} of {Patients} {With} {Alcohol} {Use} {Disorder}},\n\tvolume = {17},\n\tissn = {1541-4094},\n\turl = {https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9781615371969},\n\tdoi = {10.1176/appi.focus.17205},\n\tabstract = {(Reprinted with permission from Am J Psychiatry 2018; 175:86-90).},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {Focus (American Psychiatric Publishing)},\n\tauthor = {Reus, Victor I. and Fochtmann, Laura J. and Bukstein, Oscar and Eyler, A. Evan and Hilty, Donald M. and Horvitz-Lennon, Marcela and Mahoney, Jane and Pasic, Jagoda and Weaver, Michael and Wills, Cheryl D. and McIntyre, Jack and Kidd, Jeremy and Yager, Joel and Hong, Seung-Hee},\n\tmonth = apr,\n\tyear = {2019},\n\tpmid = {32021585},\n\tpmcid = {PMC6527005},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {158--162},\n}\n\n
\n
\n\n\n
\n (Reprinted with permission from Am J Psychiatry 2018; 175:86-90).\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Pharmacotherapies for cannabis dependence.\n \n \n \n\n\n \n Nielsen, S.; Gowing, L.; Sabioni, P.; and Le Foll, B.\n\n\n \n\n\n\n The Cochrane Database of Systematic Reviews, 1: CD008940. January 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@article{nielsen_pharmacotherapies_2019,\n\ttitle = {Pharmacotherapies for cannabis dependence},\n\tvolume = {1},\n\tissn = {1469-493X},\n\tdoi = {10.1002/14651858.CD008940.pub3},\n\tabstract = {BACKGROUND: Globally, cannabis use is prevalent and widespread. There are currently no pharmacotherapies approved for treatment of cannabis use disorders.This is an update of a Cochrane Review first published in the Cochrane Library in Issue 12, 2014.\nOBJECTIVES: To assess the effectiveness and safety of pharmacotherapies as compared with each other, placebo or no pharmacotherapy (supportive care) for reducing symptoms of cannabis withdrawal and promoting cessation or reduction of cannabis use.\nSEARCH METHODS: We updated our searches of the following databases to March 2018: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO and Web of Science.\nSELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-RCTs involving the use of medications to treat cannabis withdrawal or to promote cessation or reduction of cannabis use, or both, in comparison with other medications, placebo or no medication (supportive care) in people diagnosed as cannabis dependent or who were likely to be dependent.\nDATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane.\nMAIN RESULTS: We included 21 RCTs involving 1755 participants: 18 studies recruited adults (mean age 22 to 41 years); three studies targeted young people (mean age 20 years). Most (75\\%) participants were male. The studies were at low risk of performance, detection and selective outcome reporting bias. One study was at risk of selection bias, and three studies were at risk of attrition bias.All studies involved comparison of active medication and placebo. The medications were diverse, as were the outcomes reported, which limited the extent of analysis.Abstinence at end of treatment was no more likely with Δ9-tetrahydrocannabinol (THC) preparations than with placebo (risk ratio (RR) 0.98, 95\\% confidence interval (CI) 0.64 to 1.52; 305 participants; 3 studies; moderate-quality evidence). For selective serotonin reuptake inhibitor (SSRI) antidepressants, mixed action antidepressants, anticonvulsants and mood stabilisers, buspirone and N-acetylcysteine, there was no difference in the likelihood of abstinence at end of treatment compared to placebo (low- to very low-quality evidence).There was qualitative evidence of reduced intensity of withdrawal symptoms with THC preparations compared to placebo. For other pharmacotherapies, this outcome was either not examined, or no significant differences was reported.Adverse effects were no more likely with THC preparations (RR 1.02, 95\\% CI 0.89 to 1.17; 318 participants; 3 studies) or N-acetylcysteine (RR 0.94, 95\\% CI 0.71 to 1.23; 418 participants; 2 studies) compared to placebo (moderate-quality evidence). For SSRI antidepressants, mixed action antidepressants, buspirone and N-acetylcysteine, there was no difference in adverse effects compared to placebo (low- to very low-quality evidence).There was no difference in the likelihood of withdrawal from treatment due to adverse effects with THC preparations, SSRIs antidepressants, mixed action antidepressants, anticonvulsants and mood stabilisers, buspirone and N-acetylcysteine compared to placebo (low- to very low-quality evidence).There was no difference in the likelihood of treatment completion with THC preparations, SSRI antidepressants, mixed action antidepressants and buspirone compared to placebo (low- to very low-quality evidence) or with N-acetylcysteine compared to placebo (RR 1.06, 95\\% CI 0.93 to 1.21; 418 participants; 2 studies; moderate-quality evidence). Anticonvulsants and mood stabilisers appeared to reduce the likelihood of treatment completion (RR 0.66, 95\\% CI 0.47 to 0.92; 141 participants; 3 studies; low-quality evidence).Available evidence on gabapentin (anticonvulsant), oxytocin (neuropeptide) and atomoxetine was insufficient for estimates of effectiveness.\nAUTHORS' CONCLUSIONS: There is incomplete evidence for all of the pharmacotherapies investigated, and for many outcomes the quality of the evidence was low or very low. Findings indicate that SSRI antidepressants, mixed action antidepressants, bupropion, buspirone and atomoxetine are probably of little value in the treatment of cannabis dependence. Given the limited evidence of efficacy, THC preparations should be considered still experimental, with some positive effects on withdrawal symptoms and craving. The evidence base for the anticonvulsant gabapentin, oxytocin, and N-acetylcysteine is weak, but these medications are also worth further investigation.},\n\tlanguage = {eng},\n\tjournal = {The Cochrane Database of Systematic Reviews},\n\tauthor = {Nielsen, Suzanne and Gowing, Linda and Sabioni, Pamela and Le Foll, Bernard},\n\tmonth = jan,\n\tyear = {2019},\n\tpmid = {30687936},\n\tpmcid = {PMC6360924},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {CD008940},\n}\n\n
\n
\n\n\n
\n BACKGROUND: Globally, cannabis use is prevalent and widespread. There are currently no pharmacotherapies approved for treatment of cannabis use disorders.This is an update of a Cochrane Review first published in the Cochrane Library in Issue 12, 2014. OBJECTIVES: To assess the effectiveness and safety of pharmacotherapies as compared with each other, placebo or no pharmacotherapy (supportive care) for reducing symptoms of cannabis withdrawal and promoting cessation or reduction of cannabis use. SEARCH METHODS: We updated our searches of the following databases to March 2018: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO and Web of Science. SELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-RCTs involving the use of medications to treat cannabis withdrawal or to promote cessation or reduction of cannabis use, or both, in comparison with other medications, placebo or no medication (supportive care) in people diagnosed as cannabis dependent or who were likely to be dependent. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included 21 RCTs involving 1755 participants: 18 studies recruited adults (mean age 22 to 41 years); three studies targeted young people (mean age 20 years). Most (75%) participants were male. The studies were at low risk of performance, detection and selective outcome reporting bias. One study was at risk of selection bias, and three studies were at risk of attrition bias.All studies involved comparison of active medication and placebo. The medications were diverse, as were the outcomes reported, which limited the extent of analysis.Abstinence at end of treatment was no more likely with Δ9-tetrahydrocannabinol (THC) preparations than with placebo (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.64 to 1.52; 305 participants; 3 studies; moderate-quality evidence). For selective serotonin reuptake inhibitor (SSRI) antidepressants, mixed action antidepressants, anticonvulsants and mood stabilisers, buspirone and N-acetylcysteine, there was no difference in the likelihood of abstinence at end of treatment compared to placebo (low- to very low-quality evidence).There was qualitative evidence of reduced intensity of withdrawal symptoms with THC preparations compared to placebo. For other pharmacotherapies, this outcome was either not examined, or no significant differences was reported.Adverse effects were no more likely with THC preparations (RR 1.02, 95% CI 0.89 to 1.17; 318 participants; 3 studies) or N-acetylcysteine (RR 0.94, 95% CI 0.71 to 1.23; 418 participants; 2 studies) compared to placebo (moderate-quality evidence). For SSRI antidepressants, mixed action antidepressants, buspirone and N-acetylcysteine, there was no difference in adverse effects compared to placebo (low- to very low-quality evidence).There was no difference in the likelihood of withdrawal from treatment due to adverse effects with THC preparations, SSRIs antidepressants, mixed action antidepressants, anticonvulsants and mood stabilisers, buspirone and N-acetylcysteine compared to placebo (low- to very low-quality evidence).There was no difference in the likelihood of treatment completion with THC preparations, SSRI antidepressants, mixed action antidepressants and buspirone compared to placebo (low- to very low-quality evidence) or with N-acetylcysteine compared to placebo (RR 1.06, 95% CI 0.93 to 1.21; 418 participants; 2 studies; moderate-quality evidence). Anticonvulsants and mood stabilisers appeared to reduce the likelihood of treatment completion (RR 0.66, 95% CI 0.47 to 0.92; 141 participants; 3 studies; low-quality evidence).Available evidence on gabapentin (anticonvulsant), oxytocin (neuropeptide) and atomoxetine was insufficient for estimates of effectiveness. AUTHORS' CONCLUSIONS: There is incomplete evidence for all of the pharmacotherapies investigated, and for many outcomes the quality of the evidence was low or very low. Findings indicate that SSRI antidepressants, mixed action antidepressants, bupropion, buspirone and atomoxetine are probably of little value in the treatment of cannabis dependence. Given the limited evidence of efficacy, THC preparations should be considered still experimental, with some positive effects on withdrawal symptoms and craving. The evidence base for the anticonvulsant gabapentin, oxytocin, and N-acetylcysteine is weak, but these medications are also worth further investigation.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Lignes directrices sur le trouble lié à l'utilisation de l'alcool chez les personnes âgées.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n November 2019.\n \n\n\n\n
\n\n\n\n \n \n \"LignesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{noauthor_lignes_2019,\n\ttitle = {Lignes directrices sur le trouble lié à l'utilisation de l'alcool chez les personnes âgées},\n\turl = {https://ccsmh.ca/consommation-de-substances-et-dependance/alcool/?lang=fr},\n\tlanguage = {fr-FR},\n\turldate = {2023-03-27},\n\tjournal = {La coalition canadienne pour la santé mentale des personnes âgées},\n\tmonth = nov,\n\tyear = {2019},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Lignes directrices nationales de l’Initiative canadienne de recherche sur l’abus de substances.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance; and Institut de recherche en santé du Canada\n\n\n \n\n\n\n 2019.\n \n\n\n\n
\n\n\n\n \n \n \"LignesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 8 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_lignes_2019,\n\ttitle = {Lignes directrices nationales de l’{Initiative} canadienne de recherche sur l’abus de substances},\n\turl = {http://cran.qc.ca/sites/default/files/recommendations_fr_final.pdf},\n\turldate = {2019-08-16},\n\tauthor = {{Initiative canadienne de recherche en abus de substance} and {Institut de recherche en santé du Canada}},\n\tyear = {2019},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Provincial Guideline for the Clinical Management of High-Risk Drinking and Alcohol Use Disorder.\n \n \n \n \n\n\n \n British Columbia Centre on Substance Use\n\n\n \n\n\n\n December 2019.\n \n\n\n\n
\n\n\n\n \n \n \"ProvincialPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 6 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{british_columbia_centre_on_substance_use_provincial_2019,\n\ttitle = {Provincial {Guideline} for the {Clinical} {Management} of {High}-{Risk} {Drinking} and {Alcohol} {Use} {Disorder}},\n\turl = {https://www.bccsu.ca/wp-content/uploads/2020/03/AUD-Guideline.pdf},\n\turldate = {2020-09-28},\n\tauthor = {{British Columbia Centre on Substance Use}},\n\tmonth = dec,\n\tyear = {2019},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2018\n \n \n (11)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Guide de pratique pour le traitement cognitif-comportemental des troubles psychotiques.\n \n \n \n \n\n\n \n Paquette Houde, C.; Abdel Baki, A.; Lecomte, T.; Lussier-Valade, M.; and Ngô, T.\n\n\n \n\n\n\n Technical Report 2018.\n \n\n\n\n
\n\n\n\n \n \n \"GuidePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@techreport{paquette_houde_guide_2018,\n\ttitle = {Guide de pratique pour le traitement cognitif-comportemental des troubles psychotiques},\n\turl = {https://tccmontreal.files.wordpress.com/2018/10/guidetccp_16-final-22-10-2018-version-isbn.pdf},\n\turldate = {2022-03-07},\n\tauthor = {Paquette Houde, C. and Abdel Baki, A. and Lecomte, T. and Lussier-Valade, M. and Ngô, T.L.},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Le médecin et le consentement aux soins.\n \n \n \n \n\n\n \n Collège des médecins du Québec; and Barreau du Québec\n\n\n \n\n\n\n 2018.\n \n\n\n\n
\n\n\n\n \n \n \"LePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{college_des_medecins_du_quebec_medecin_2018,\n\ttitle = {Le médecin et le consentement aux soins},\n\turl = {https://www.barreau.qc.ca/media/1580/medecin-consentement-soins.pdf#page=17},\n\turldate = {2019-08-16},\n\tauthor = {{Collège des médecins du Québec} and {Barreau du Québec}},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.\n \n \n \n \n\n\n \n Crunelle, C. L.; van den Brink, W.; Moggi, F.; Konstenius, M.; Franck, J.; Levin, F. R.; van de Glind, G.; Demetrovics, Z.; Coetzee, C.; Luderer, M.; Schellekens, A.; ICASA consensus group; and Matthys, F.\n\n\n \n\n\n\n European Addiction Research, 24(1): 43–51. 2018.\n \n\n\n\n
\n\n\n\n \n \n \"InternationalPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@article{crunelle_international_2018,\n\ttitle = {International {Consensus} {Statement} on {Screening}, {Diagnosis} and {Treatment} of {Substance} {Use} {Disorder} {Patients} with {Comorbid} {Attention} {Deficit}/{Hyperactivity} {Disorder}},\n\tvolume = {24},\n\tissn = {1421-9891},\n\turl = {https://pubmed.ncbi.nlm.nih.gov/29510390/},\n\tdoi = {10.1159/000487767},\n\tabstract = {Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.},\n\tlanguage = {eng},\n\tnumber = {1},\n\tjournal = {European Addiction Research},\n\tauthor = {Crunelle, Cleo L. and van den Brink, Wim and Moggi, Franz and Konstenius, Maija and Franck, Johan and Levin, Frances R. and van de Glind, Geurt and Demetrovics, Zsolt and Coetzee, Corné and Luderer, Mathias and Schellekens, Arnt and {ICASA consensus group} and Matthys, Frieda},\n\tyear = {2018},\n\tpmid = {29510390},\n\tpmcid = {PMC5986068},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {43--51},\n}\n\n
\n
\n\n\n
\n Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Treatment of Personality Disorders in Adults with or without Comorbid Mental Health Conditions: Clinical Effectiveness and Guidelines.\n \n \n \n \n\n\n \n CADTH\n\n\n \n\n\n\n Technical Report 2018.\n \n\n\n\n
\n\n\n\n \n \n \"TreatmentPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@techreport{cadth_treatment_2018,\n\ttype = {Rapid {Response} {Report}},\n\ttitle = {Treatment of {Personality} {Disorders} in {Adults} with or without {Comorbid} {Mental} {Health} {Conditions}: {Clinical} {Effectiveness} and {Guidelines}},\n\turl = {https://cadth.ca/sites/default/files/pdf/htis/2018/RB1199%20Personality%20Disorders%20Final.pdf},\n\turldate = {2022-04-26},\n\tauthor = {CADTH},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Buprénorphine (chlorhydarte de) (ProbuphineMC) : Demande d’autorisation de paiement pour les médicaments d’exception \\textbar Traitement substitutif de la dépendance aux opioïdes.\n \n \n \n \n\n\n \n RAMQ\n\n\n \n\n\n\n 2018.\n \n\n\n\n
\n\n\n\n \n \n \"BuprénorphinePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{ramq_buprenorphine_2018,\n\ttitle = {Buprénorphine (chlorhydarte de) ({ProbuphineMC}) : {Demande} d’autorisation de paiement pour les médicaments d’exception {\\textbar} {Traitement} substitutif de la dépendance aux opioïdes},\n\turl = {https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/formulaires/8210.pdf},\n\turldate = {2020-06-10},\n\tauthor = {{RAMQ}},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Administration de la naloxone par voie nasale.\n \n \n \n \n\n\n \n Institut national d'excellence en santé et en services sociaux\n\n\n \n\n\n\n 2018.\n \n\n\n\n
\n\n\n\n \n \n \"AdministrationPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{institut_national_dexcellence_en_sante_et_en_services_sociaux_administration_2018,\n\ttitle = {Administration de la naloxone par voie nasale},\n\turl = {https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/Naloxone_NAS_12-FR.pdf},\n\turldate = {2019-09-19},\n\tauthor = {{Institut national d'excellence en santé et en services sociaux}},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Administration de la naloxone par injection.\n \n \n \n \n\n\n \n Institut national d'excellence en santé et en services sociaux\n\n\n \n\n\n\n 2018.\n \n\n\n\n
\n\n\n\n \n \n \"AdministrationPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{institut_national_dexcellence_en_sante_et_en_services_sociaux_administration_2018-1,\n\ttitle = {Administration de la naloxone par injection},\n\turl = {https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/Naloxone_INJ_12-FR.pdf},\n\turldate = {2019-09-19},\n\tauthor = {{Institut national d'excellence en santé et en services sociaux}},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders.\n \n \n \n\n\n \n Rømer Thomsen, K.; Thylstrup, B.; Pedersen, M. M.; Pedersen, M. U.; Simonsen, E.; and Hesse, M.\n\n\n \n\n\n\n Schizophrenia Research, 195: 495–500. 2018.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@article{romer_thomsen_drug-related_2018,\n\ttitle = {Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders},\n\tvolume = {195},\n\tissn = {1573-2509},\n\tdoi = {10.1016/j.schres.2017.09.026},\n\tabstract = {BACKGROUND: Patients with schizophrenia and comorbid drug use disorders (DUD) have a severe course of illness. Despite strong evidence that drug use can exacerbate psychotic symptoms, we have limited knowledge of how specific drugs may increase risk of schizophrenia readmission in this group. This study aimed to assess drug-related predictors of readmission for schizophrenia among a national cohort of patients with a history of schizophrenia admitted to DUD treatment.\nMETHODS: A record-linkage study was used to assess drug-related factors associated with readmission to mental health treatment for schizophrenia, using a consecutive cohort of 634 patients admitted to DUD treatment between 2000 and 2006 in Danish treatment services and tracked until February 2013 or death, controlling for baseline psychiatric treatment variables.\nRESULTS: The majority of patients were males (79.8\\%) and the mean age was 34.7years. Of all patients, 78.7\\% were readmitted for schizophrenia during follow-up, and 6.8\\% died without having been readmitted. We found a robust association between use of amphetamine at baseline and elevated risk of readmission, a less robust association between use of cannabis and elevated risk of readmission, and no association with cocaine, opioids, alcohol, benzodiazepines, and MDMA. Furthermore, one or more psychiatric inpatients visit in the year prior to DUD admission was robustly associated with elevated risk of schizophrenia readmission.\nCONCLUSIONS: Use of amphetamine and cannabis are risk markers for schizophrenia readmission among patients with a history of schizophrenia and DUD. Psychiatric history is a predictor of schizophrenia readmission in this patient group.},\n\tlanguage = {eng},\n\tjournal = {Schizophrenia Research},\n\tauthor = {Rømer Thomsen, Kristine and Thylstrup, Birgitte and Pedersen, Michael Mulbjerg and Pedersen, Mads Uffe and Simonsen, Erik and Hesse, Morten},\n\tyear = {2018},\n\tpmid = {28965780},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {495--500},\n}\n\n
\n
\n\n\n
\n BACKGROUND: Patients with schizophrenia and comorbid drug use disorders (DUD) have a severe course of illness. Despite strong evidence that drug use can exacerbate psychotic symptoms, we have limited knowledge of how specific drugs may increase risk of schizophrenia readmission in this group. This study aimed to assess drug-related predictors of readmission for schizophrenia among a national cohort of patients with a history of schizophrenia admitted to DUD treatment. METHODS: A record-linkage study was used to assess drug-related factors associated with readmission to mental health treatment for schizophrenia, using a consecutive cohort of 634 patients admitted to DUD treatment between 2000 and 2006 in Danish treatment services and tracked until February 2013 or death, controlling for baseline psychiatric treatment variables. RESULTS: The majority of patients were males (79.8%) and the mean age was 34.7years. Of all patients, 78.7% were readmitted for schizophrenia during follow-up, and 6.8% died without having been readmitted. We found a robust association between use of amphetamine at baseline and elevated risk of readmission, a less robust association between use of cannabis and elevated risk of readmission, and no association with cocaine, opioids, alcohol, benzodiazepines, and MDMA. Furthermore, one or more psychiatric inpatients visit in the year prior to DUD admission was robustly associated with elevated risk of schizophrenia readmission. CONCLUSIONS: Use of amphetamine and cannabis are risk markers for schizophrenia readmission among patients with a history of schizophrenia and DUD. Psychiatric history is a predictor of schizophrenia readmission in this patient group.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Lignes Directrices Nationales de L'Initiative Canadienne de Recherche sur l'Abus de Substances sur la Prise en Charge Clinique du trouble lié à l'usage d'opioïdes.\n \n \n \n \n\n\n \n Institut de recherche en santé du Canada\n\n\n \n\n\n\n 2018.\n \n\n\n\n
\n\n\n\n \n \n \"LignesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{institut_de_recherche_en_sante_du_canada_lignes_2018,\n\ttitle = {Lignes {Directrices} {Nationales} de {L}'{Initiative} {Canadienne} de {Recherche} sur l'{Abus} de {Substances}  sur la {Prise} en {Charge} {Clinique} du trouble lié à l'usage d'opioïdes},\n\turl = {https://crism.ca/wp-content/uploads/2018/03/CRISM_NationalGuideline_OUD-FRENCH.pdf},\n\tlanguage = {français},\n\turldate = {2018-04-18},\n\tauthor = {{Institut de recherche en santé du Canada}},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n PROBUPHINE – Traitement substitutif de la dépendance aux opioïdes Avis transmis au ministre en septembre 2018.\n \n \n \n \n\n\n \n INESSS\n\n\n \n\n\n\n Technical Report 2018.\n \n\n\n\n
\n\n\n\n \n \n \"PROBUPHINEPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@techreport{inesss_probuphine_2018,\n\ttitle = {{PROBUPHINE} – {Traitement} substitutif de la dépendance aux opioïdes {Avis} transmis au ministre en septembre 2018},\n\turl = {https://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avis_au_ministre/Octobre_2018/Probuphine_2018_09.pdf},\n\tauthor = {{INESSS}},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Lignes directrices nationales de L’Initiative canadienne de recherche sur l’abus de substances sur la prise en charge clinique du trouble lié à l’usage d’opioïdes.\n \n \n \n \n\n\n \n Initiative canadienne de recherche en abus de substance; and Institut de recherche en santé du Canada\n\n\n \n\n\n\n 2018.\n \n\n\n\n
\n\n\n\n \n \n \"LignesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{initiative_canadienne_de_recherche_en_abus_de_substance_lignes_2018,\n\ttitle = {Lignes directrices nationales de {L}’{Initiative} canadienne de recherche sur l’abus de substances sur la prise en charge clinique du trouble lié à l’usage d’opioïdes},\n\turl = {http://www.cmaj.ca/content/cmaj/suppl/2018/02/27/190.9.E247.DC1/170958-guide-1-at.pdf#page=134},\n\turldate = {2019-08-16},\n\tauthor = {{Initiative canadienne de recherche en abus de substance} and {Institut de recherche en santé du Canada}},\n\tyear = {2018},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2017\n \n \n (3)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders.\n \n \n \n \n\n\n \n Crockford, D.; and Addington, D.\n\n\n \n\n\n\n Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 62(9): 624–634. 2017.\n \n\n\n\n
\n\n\n\n \n \n \"CanadianPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@article{crockford_canadian_2017,\n\ttitle = {Canadian {Schizophrenia} {Guidelines}: {Schizophrenia} and {Other} {Psychotic} {Disorders} with {Coexisting} {Substance} {Use} {Disorders}},\n\tvolume = {62},\n\tissn = {1497-0015},\n\tshorttitle = {Canadian {Schizophrenia} {Guidelines}},\n\turl = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593250/pdf/10.1177_0706743717720196.pdf},\n\tdoi = {10.1177/0706743717720196},\n\tabstract = {OBJECTIVE: Persons with schizophrenia and other psychotic disorders frequently have coexisting substance use disorders that require modifications to treatment approaches for best outcomes. The objectives of this review were to identify evidence-based practices best practices that improve outcomes for individuals with schizophrenia and substance used disorders.\nMETHOD: We reviewed guidelines that were published in the last 5 years and that included systematic reviews or meta-analyses. Most of our recommendations came from 2 publications from the National Institute for Health and Care Excellence (NICE): the 2011 guidance titled Coexisting Severe Mental Illness (Psychosis) and Substance Misuse: Assessment and Management in Healthcare Settings and the 2014 guidance titled Psychosis and Schizophrenia in Adults: Prevention and Management. We placed these recommendations into the Canadian context to create this guideline.\nRESULTS: Evidence supports the inclusion of individuals with coexisting substance use disorders in first-episode psychosis programs. The programs should integrate psychosis and substance use treatments, emphasizing ongoing monitoring of both substance use and patterns and symptoms. The best outcomes are achieved with combined use of antipsychotic medications and addiction-based psychosocial interventions. However, limited evidence is available to recommend using one antipsychotic medication over another or one psychosocial intervention over another for persons with schizophrenia and other psychotic disorders with coexisting substance use disorders.\nCONCLUSIONS: Treating persons who have schizophrenia and other psychotic disorders with coexisting substance use disorders can present clinical challenges, but modifications in practice can help engage and retain people in treatment, where significant improvements over time can be expected.},\n\tlanguage = {eng},\n\tnumber = {9},\n\tjournal = {Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie},\n\tauthor = {Crockford, David and Addington, Donald},\n\tyear = {2017},\n\tpmid = {28886671},\n\tpmcid = {PMC5593250},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {624--634},\n}\n\n
\n
\n\n\n
\n OBJECTIVE: Persons with schizophrenia and other psychotic disorders frequently have coexisting substance use disorders that require modifications to treatment approaches for best outcomes. The objectives of this review were to identify evidence-based practices best practices that improve outcomes for individuals with schizophrenia and substance used disorders. METHOD: We reviewed guidelines that were published in the last 5 years and that included systematic reviews or meta-analyses. Most of our recommendations came from 2 publications from the National Institute for Health and Care Excellence (NICE): the 2011 guidance titled Coexisting Severe Mental Illness (Psychosis) and Substance Misuse: Assessment and Management in Healthcare Settings and the 2014 guidance titled Psychosis and Schizophrenia in Adults: Prevention and Management. We placed these recommendations into the Canadian context to create this guideline. RESULTS: Evidence supports the inclusion of individuals with coexisting substance use disorders in first-episode psychosis programs. The programs should integrate psychosis and substance use treatments, emphasizing ongoing monitoring of both substance use and patterns and symptoms. The best outcomes are achieved with combined use of antipsychotic medications and addiction-based psychosocial interventions. However, limited evidence is available to recommend using one antipsychotic medication over another or one psychosocial intervention over another for persons with schizophrenia and other psychotic disorders with coexisting substance use disorders. CONCLUSIONS: Treating persons who have schizophrenia and other psychotic disorders with coexisting substance use disorders can present clinical challenges, but modifications in practice can help engage and retain people in treatment, where significant improvements over time can be expected.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Guide d’accompagnement pour le déploiement d’une offre de service de 1re ligne en santé mentale adulte (SMA).\n \n \n \n \n\n\n \n Centre national d'excellence en santé mentale\n\n\n \n\n\n\n 2017.\n \n\n\n\n
\n\n\n\n \n \n \"GuidePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 10 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{centre_national_dexcellence_en_sante_mentale_guide_2017,\n\ttitle = {Guide d’accompagnement pour le déploiement d’une offre de service de 1re ligne en santé mentale adulte ({SMA})},\n\turl = {http://www.douglas.qc.ca/uploads/File/Guide_accompagnement_Premiere_ligne.pdf},\n\tauthor = {{Centre national d'excellence en santé mentale}},\n\tyear = {2017},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Opioid Use Disorder: A guideline for the Clinical Management.\n \n \n \n \n\n\n \n British Columbia Centre on Substance Use\n\n\n \n\n\n\n 2017.\n \n\n\n\n
\n\n\n\n \n \n \"OpioidPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{british_columbia_centre_on_substance_use_opioid_2017,\n\ttitle = {Opioid {Use} {Disorder}: {A} guideline for the {Clinical} {Management}},\n\turl = {http://www.bccsu.ca/wp-content/uploads/2017/06/BC-OUD-Guidelines_June2017.pdf},\n\turldate = {2019-08-16},\n\tauthor = {{British Columbia Centre on Substance Use}},\n\tyear = {2017},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2016\n \n \n (2)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Guidelines on the management of co-occurring alcohol and other drug and mental health conditions in alcohol and other drug treatment settings (second edition).\n \n \n \n \n\n\n \n Marel, C.; Mills, K. L; Kingston, R.; Gournay, K.; Deady, M.; Kay-Lambkin, F.; Baker, F.; and Teesson, M.\n\n\n \n\n\n\n 2016.\n \n\n\n\n
\n\n\n\n \n \n \"GuidelinesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{marel_guidelines_2016,\n\ttitle = {Guidelines on the management of co-occurring alcohol and other drug and mental health conditions in alcohol and other drug treatment settings (second edition)},\n\turl = {https://comorbidity.edu.au/cre-resources/guidelines-management-co-occurring-alcohol-and-other-drug-and-mental-health-0},\n\turldate = {2018-07-04},\n\tauthor = {Marel, Christina and Mills, Katherine L and Kingston, Rosemary and Gournay, Kevin and Deady, Mark and Kay-Lambkin, Frances and Baker, Frances and Teesson, Maree},\n\tyear = {2016},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Psychostimulant drugs for cocaine dependence.\n \n \n \n \n\n\n \n Castells, X.; Cunill, R.; Pérez-Mañá, C.; Vidal, X.; and Capellà, D.\n\n\n \n\n\n\n The Cochrane Database of Systematic Reviews, 9: CD007380. September 2016.\n \n\n\n\n
\n\n\n\n \n \n \"PsychostimulantPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@article{castells_psychostimulant_2016,\n\ttitle = {Psychostimulant drugs for cocaine dependence},\n\tvolume = {9},\n\tissn = {1469-493X},\n\turl = {https://www.ncbi.nlm.nih.gov/pubmed/27670244},\n\tdoi = {10.1002/14651858.CD007380.pub4},\n\tabstract = {BACKGROUND: Cocaine dependence is a severe disorder for which no medication has been approved. Like opioids for heroin dependence, replacement therapy with psychostimulants could be an effective therapy for treatment.\nOBJECTIVES: To assess the effects of psychostimulants for cocaine abuse and dependence. Specific outcomes include sustained cocaine abstinence and retention in treatment. We also studied the influence of type of drug and comorbid disorders on psychostimulant efficacy.\nSEARCH METHODS: This is an update of the review previously published in 2010. For this updated review, we searched the Cochrane Drugs and Alcohol Group Trials Register, CENTRAL, MEDLINE, Embase and PsycINFO up to 15 February 2016. We handsearched references of obtained articles and consulted experts in the field.\nSELECTION CRITERIA: We included randomised parallel group controlled clinical trials comparing the efficacy of a psychostimulant drug versus placebo.\nDATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane.\nMAIN RESULTS: We included 26 studies involving 2366 participants. The included studies assessed nine drugs: bupropion, dexamphetamine, lisdexamfetamine, methylphenidate, modafinil, mazindol, methamphetamine, mixed amphetamine salts and selegiline. We did not consider any study to be at low risk of bias for all domains included in the Cochrane 'Risk of bias' tool. Attrition bias was the most frequently suspected potential source of bias of the included studies. We found very low quality evidence that psychostimulants improved sustained cocaine abstinence (risk ratio (RR) 1.36, 95\\% confidence interval (CI) 1.05 to 1.77, P = 0.02), but they did not reduce cocaine use (standardised mean difference (SMD) 0.16, 95\\% CI -0.02 to 0.33) among participants who continued to use it. Furthermore, we found moderate quality evidence that psychostimulants did not improve retention in treatment (RR 1.00, 95\\% CI 0.93 to 1.06). The proportion of adverse event-induced dropouts and cardiovascular adverse event-induced dropouts was similar for psychostimulants and placebo (RD 0.00, 95\\% CI -0.01 to 0.01; RD 0.00, 95\\% CI -0.02 to 0.01, respectively). When we included the type of drug as a moderating variable, the proportion of patients achieving sustained cocaine abstinence was higher with bupropion and dexamphetamine than with placebo. Psychostimulants also appeared to increase the proportion of patients achieving sustained cocaine and heroin abstinence amongst methadone-maintained, dual heroin-cocaine addicts. Retention to treatment was low, though, so our results may be compromised by attrition bias. We found no evidence of publication bias.\nAUTHORS' CONCLUSIONS: This review found mixed results. Psychostimulants improved cocaine abstinence compared to placebo in some analyses but did not improve treatment retention. Since treatment dropout was high, we cannot rule out the possibility that these results were influenced by attrition bias. Existing evidence does not clearly demonstrate the efficacy of any pharmacological treatment for cocaine dependence, but substitution treatment with psychostimulants appears promising and deserves further investigation.},\n\tlanguage = {eng},\n\tjournal = {The Cochrane Database of Systematic Reviews},\n\tauthor = {Castells, Xavier and Cunill, Ruth and Pérez-Mañá, Clara and Vidal, Xavier and Capellà, Dolors},\n\tmonth = sep,\n\tyear = {2016},\n\tpmid = {27670244},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n\tpages = {CD007380},\n}\n\n
\n
\n\n\n
\n BACKGROUND: Cocaine dependence is a severe disorder for which no medication has been approved. Like opioids for heroin dependence, replacement therapy with psychostimulants could be an effective therapy for treatment. OBJECTIVES: To assess the effects of psychostimulants for cocaine abuse and dependence. Specific outcomes include sustained cocaine abstinence and retention in treatment. We also studied the influence of type of drug and comorbid disorders on psychostimulant efficacy. SEARCH METHODS: This is an update of the review previously published in 2010. For this updated review, we searched the Cochrane Drugs and Alcohol Group Trials Register, CENTRAL, MEDLINE, Embase and PsycINFO up to 15 February 2016. We handsearched references of obtained articles and consulted experts in the field. SELECTION CRITERIA: We included randomised parallel group controlled clinical trials comparing the efficacy of a psychostimulant drug versus placebo. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included 26 studies involving 2366 participants. The included studies assessed nine drugs: bupropion, dexamphetamine, lisdexamfetamine, methylphenidate, modafinil, mazindol, methamphetamine, mixed amphetamine salts and selegiline. We did not consider any study to be at low risk of bias for all domains included in the Cochrane 'Risk of bias' tool. Attrition bias was the most frequently suspected potential source of bias of the included studies. We found very low quality evidence that psychostimulants improved sustained cocaine abstinence (risk ratio (RR) 1.36, 95% confidence interval (CI) 1.05 to 1.77, P = 0.02), but they did not reduce cocaine use (standardised mean difference (SMD) 0.16, 95% CI -0.02 to 0.33) among participants who continued to use it. Furthermore, we found moderate quality evidence that psychostimulants did not improve retention in treatment (RR 1.00, 95% CI 0.93 to 1.06). The proportion of adverse event-induced dropouts and cardiovascular adverse event-induced dropouts was similar for psychostimulants and placebo (RD 0.00, 95% CI -0.01 to 0.01; RD 0.00, 95% CI -0.02 to 0.01, respectively). When we included the type of drug as a moderating variable, the proportion of patients achieving sustained cocaine abstinence was higher with bupropion and dexamphetamine than with placebo. Psychostimulants also appeared to increase the proportion of patients achieving sustained cocaine and heroin abstinence amongst methadone-maintained, dual heroin-cocaine addicts. Retention to treatment was low, though, so our results may be compromised by attrition bias. We found no evidence of publication bias. AUTHORS' CONCLUSIONS: This review found mixed results. Psychostimulants improved cocaine abstinence compared to placebo in some analyses but did not improve treatment retention. Since treatment dropout was high, we cannot rule out the possibility that these results were influenced by attrition bias. Existing evidence does not clearly demonstrate the efficacy of any pharmacological treatment for cocaine dependence, but substitution treatment with psychostimulants appears promising and deserves further investigation.\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2015\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Guide d'intervention en dépendance, dans un contexte de concomitance d'un problème mental.\n \n \n \n \n\n\n \n Association des intervenants en dépendance du Québec,\n editor.\n \n\n\n \n\n\n\n Association des intervenants en dépendance du Québec (AIDQ), Montréal, Québec, 2015.\n \n\n\n\n
\n\n\n\n \n \n \"GuidePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 10 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@book{association_des_intervenants_en_dependance_du_quebec_guide_2015,\n\taddress = {Montréal, Québec},\n\ttitle = {Guide d'intervention en dépendance, dans un contexte de concomitance d'un problème mental},\n\tisbn = {978-2-921628-36-5},\n\turl = {http://catalogue.santecom.qc.ca/cgi-bin/koha/opac-detail.pl?biblionumber=65233},\n\tpublisher = {Association des intervenants en dépendance du Québec (AIDQ)},\n\teditor = {{Association des intervenants en dépendance du Québec}},\n\tyear = {2015},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2013\n \n \n (2)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n TIP 48: Managing Depressive Symptoms in Substance Abuse Clients During Early Recovery.\n \n \n \n \n\n\n \n SAMHSA - Substance Abuse; and Administration, M. H. S.\n\n\n \n\n\n\n 2013.\n \n\n\n\n
\n\n\n\n \n \n \"TIPPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{samhsa_-_substance_abuse_and_mental_health_services_administration_tip_2013,\n\ttitle = {{TIP} 48: {Managing} {Depressive} {Symptoms} in {Substance} {Abuse} {Clients} {During} {Early} {Recovery}},\n\tshorttitle = {{TIP} 48},\n\turl = {https://store.samhsa.gov/product/TIP-48-Managing-Depressive-Symptoms-in-Substance-Abuse-Clients-During-Early-Recovery/SMA13-4353},\n\tabstract = {This guide helps substance use counselors treat clients with symptoms of depression and substance use conditions. Program administrators will learn how to integrate depression treatment into early drug treatment. The guidelines cover screening, assessment, treatment, counseling, cultural competence, and continuing care. Access the literature review.},\n\tlanguage = {en-US},\n\turldate = {2018-07-04},\n\tauthor = {{SAMHSA - Substance Abuse and Mental Health Services Administration}},\n\tyear = {2013},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n
\n This guide helps substance use counselors treat clients with symptoms of depression and substance use conditions. Program administrators will learn how to integrate depression treatment into early drug treatment. The guidelines cover screening, assessment, treatment, counseling, cultural competence, and continuing care. Access the literature review.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n TIP 42: Substance Abuse Treatment For Persons With Co-Occurring Disorders : A Treatment Improvement Protocol.\n \n \n \n \n\n\n \n SAMHSA - Substance Abuse; and Administration, M. H. S.\n\n\n \n\n\n\n 2013.\n \n\n\n\n
\n\n\n\n \n \n \"TIPPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{samhsa_-_substance_abuse_and_mental_health_services_administration_tip_2013-1,\n\ttitle = {{TIP} 42: {Substance} {Abuse} {Treatment} {For} {Persons} {With} {Co}-{Occurring} {Disorders} : {A} {Treatment} {Improvement} {Protocol}},\n\turl = {https://store.samhsa.gov/system/files/sma13-3992.pdf},\n\turldate = {2018-07-04},\n\tauthor = {{SAMHSA - Substance Abuse and Mental Health Services Administration}},\n\tyear = {2013},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2012\n \n \n (2)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Coexisting severe mental illness and substance misuse: assessment and management in healthcare settings overview - NICE Pathways.\n \n \n \n \n\n\n \n National Institute for Health; and (NICE), C. E.\n\n\n \n\n\n\n 2012.\n \n\n\n\n
\n\n\n\n \n \n \"CoexistingPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{national_institute_for_health_and_care_excellence_nice_coexisting_2012,\n\ttitle = {Coexisting severe mental illness and substance misuse: assessment and management in healthcare settings overview - {NICE} {Pathways}},\n\turl = {https://pathways.nice.org.uk/pathways/coexisting-severe-mental-illness-and-substance-misuse-assessment-and-management-in-healthcare-settings},\n\turldate = {2019-08-07},\n\tauthor = {{National Institute for Health and Care Excellence (NICE)}},\n\tyear = {2012},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Notions de base sur les maladies mentales : guide pratique d'intervention.\n \n \n \n \n\n\n \n Institut universitaire en santé mentale de Québec\n\n\n \n\n\n\n 2012.\n \n\n\n\n
\n\n\n\n \n \n \"NotionsPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 4 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{institut_universitaire_en_sante_mentale_de_quebec_notions_2012,\n\ttitle = {Notions de base sur les maladies mentales : guide pratique d'intervention},\n\turl = {https://www.ciusss-capitalenationale.gouv.qc.ca/sites/default/files/guide-notions-bases-maladies-mentales.pdf},\n\tauthor = {{Institut universitaire en santé mentale de Québec}},\n\tyear = {2012},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2010\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Routes to recovery: psychosocial interventions for drug misuse: a framework and toolkit for implementing NICE recommended treatment interventions.\n \n \n \n \n\n\n \n NHS National Treatment Agency for Substance Misuse\n\n\n \n\n\n\n 2010.\n \n\n\n\n
\n\n\n\n \n \n \"RoutesPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{nhs_national_treatment_agency_for_substance_misuse_routes_2010,\n\ttitle = {Routes to recovery: psychosocial interventions for drug misuse: a framework and toolkit for implementing {NICE} recommended treatment interventions},\n\turl = {https://www.bl.uk/collection-items/routes-to-recovery-psychosocial-interventions-for-drug-misuse-a-framework-and-toolkit-for-implementing-nicerecommended-treatment-interventions},\n\tabstract = {Toolkit for use of psychosocial interventions in management of drug misuse and common mental health problems},\n\tlanguage = {eng},\n\turldate = {2020-10-20},\n\tpublisher = {The British Library},\n\tauthor = {{NHS National Treatment Agency for Substance Misuse}},\n\tyear = {2010},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n
\n Toolkit for use of psychosocial interventions in management of drug misuse and common mental health problems\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2009\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n La buprénorphine dans le traitement de la dépendance aux opioïdes : lignes directrices.\n \n \n \n \n\n\n \n Collège des médecins du Québec; and Ordre des pharmaciens du Québec\n\n\n \n\n\n\n 2009.\n \n\n\n\n
\n\n\n\n \n \n \"LaPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{college_des_medecins_du_quebec_buprenorphine_2009,\n\ttitle = {La buprénorphine dans le traitement de la dépendance aux opioïdes : lignes directrices},\n\turl = {https://www.opq.org/doc/media/808_38_fr-ca_0_ld_buprenorphone.pdf},\n\turldate = {2020-04-20},\n\tauthor = {{Collège des médecins du Québec} and {Ordre des pharmaciens du Québec}},\n\tyear = {2009},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n undefined\n \n \n (9)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Thérapie cognitivo-comportementale: guides de pratiques et autres outils.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"ThérapiePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{noauthor_therapie_nodate,\n\ttitle = {Thérapie cognitivo-comportementale: guides de pratiques et autres outils},\n\turl = {https://tccmontreal.com/},\n\tlanguage = {fr-CA},\n\turldate = {2022-11-15},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n L’approche de réduction des méfaits.\n \n \n \n \n\n\n \n Brisson, P.\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"L’approchePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{brisson_lapproche_nodate,\n\ttitle = {L’approche de réduction des méfaits},\n\turl = {https://www.inspq.qc.ca/espace-itss/l-approche-de-reduction-des-mefaits},\n\tabstract = {L’expression « réduction des méfaits » a été adoptée par le Québec – et les traducteurs du Canada anglais – comme traduction du terme harm reduction, proposé par les Britanniques lors de l’apparition de l’approche et qui s’est imposé comme appellation de référence. Les Européens (France, Suisse, Belgique) utilisent quant à eux la traduction moins littérale de « réduction des risques ».},\n\tlanguage = {fr},\n\turldate = {2019-08-16},\n\tjournal = {INSPQ},\n\tauthor = {Brisson, P.},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n
\n L’expression « réduction des méfaits » a été adoptée par le Québec – et les traducteurs du Canada anglais – comme traduction du terme harm reduction, proposé par les Britanniques lors de l’apparition de l’approche et qui s’est imposé comme appellation de référence. Les Européens (France, Suisse, Belgique) utilisent quant à eux la traduction moins littérale de « réduction des risques ».\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Implementing Seeking Safety therapy for PTSD and substance abuse: Clinical Guidelines.\n \n \n \n \n\n\n \n Najavits, L. M.\n\n\n \n\n\n\n Technical Report .\n \n\n\n\n
\n\n\n\n \n \n \"ImplementingPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@techreport{najavits_implementing_nodate,\n\ttitle = {Implementing {Seeking} {Safety} therapy for {PTSD} and substance abuse: {Clinical} {Guidelines}},\n\turl = {http://citeseerx.ist.psu.edu/viewdoc/download;jsessionid=4923A1F071BC9F7D6977BB8D1574CB07?doi=10.1.1.152.3287&rep=rep1&type=pdf},\n\turldate = {2022-04-19},\n\tauthor = {Najavits, Lisa M.},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Grille d'évaluation de la personne à risque suicidaire.\n \n \n \n \n\n\n \n québécoise des infirmières et infirmiers en santé mentale , A.\n\n\n \n\n\n\n Technical Report .\n \n\n\n\n
\n\n\n\n \n \n \"GrillePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@techreport{association_quebecoise_des_infirmieres_et_infirmiers_en_sante_mentale_grille_nodate,\n\ttitle = {Grille d'évaluation de la personne à risque suicidaire},\n\turl = {https://aqiism.org/wp-content/uploads/Outil-clinique-Guide-d%C3%A9valuation-du-risque-suicidaire-_-m%C3%A0j-09-2019.pdf},\n\turldate = {2022-02-15},\n\tauthor = {Association québécoise des infirmières et infirmiers en santé mentale},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Justice et santé mentale : une alternative à l’emprisonnement.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"JusticePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{noauthor_justice_nodate,\n\ttitle = {Justice et santé mentale : une alternative à l’emprisonnement},\n\tshorttitle = {Justice et santé mentale},\n\turl = {https://www.quebec.ca/nouvelles/actualites/details/sante-mentale-alternative-emprisonnement},\n\tabstract = {En matière de santé mentale, l’emprisonnement ne règle souvent rien. Solution pour enrayer le phénomène dit des portes tournantes.},\n\tlanguage = {fr},\n\turldate = {2023-03-21},\n\tjournal = {Gouvernement du Québec},\n\tkeywords = {Lignes directrices et prise en charge psychosociale},\n}\n\n
\n
\n\n\n
\n En matière de santé mentale, l’emprisonnement ne règle souvent rien. Solution pour enrayer le phénomène dit des portes tournantes.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Algorithme de prise en charge de la douleur neuropathique - Publications du ministère de la Santé et des Services sociaux.\n \n \n \n \n\n\n \n \n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"AlgorithmePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{noauthor_algorithme_nodate,\n\ttitle = {Algorithme de prise en charge de la douleur neuropathique - {Publications} du ministère de la {Santé} et des {Services} sociaux},\n\turl = {https://publications.msss.gouv.qc.ca/msss/document-001058/},\n\turldate = {2023-04-14},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Évaluation des syndromes de sevrage dans un établissement clinique selon l’échelle de l’alcoolisme (CIWA-Ar).\n \n \n \n \n\n\n \n MSD Manuals\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"ÉvaluationPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{msd_manuals_evaluation_nodate,\n\ttitle = {Évaluation des syndromes de sevrage dans un établissement clinique selon l’échelle de l’alcoolisme ({CIWA}-{Ar})},\n\turl = {https://www.msdmanuals.com/medical-calculators/CIWA-fr.htm},\n\turldate = {2020-06-11},\n\tauthor = {{MSD Manuals}},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Échelle COWS.\n \n \n \n \n\n\n \n Hôpitaux Universitaires Genève\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"ÉchellePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{hopitaux_universitaires_geneve_echelle_nodate,\n\ttitle = {Échelle {COWS}},\n\turl = {https://pro.addictohug.ch/cows/},\n\turldate = {2020-06-10},\n\tauthor = {{Hôpitaux Universitaires Genève}},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Prise en charge du sevrage au Canada : rapport sur les indicateurs nationaux de traitement (Données de 2015-2016).\n \n \n \n \n\n\n \n Centre canadien sur les dépendances et l’usage de substances\n\n\n \n\n\n\n \n \n\n\n\n
\n\n\n\n \n \n \"PrisePaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n
@misc{centre_canadien_sur_les_dependances_et_lusage_de_substances_prise_nodate,\n\ttitle = {Prise en charge du sevrage au {Canada} : rapport sur les indicateurs nationaux de traitement ({Données} de 2015-2016)},\n\tshorttitle = {Prise en charge du sevrage au {Canada}},\n\turl = {https://www.ccsa.ca/fr/prise-en-charge-du-sevrage-au-canada-rapport-sur-les-indicateurs-nationaux-de-traitement-donnees-de},\n\tabstract = {Ce rapport s’inscrit dans une série sur les indicateurs nationaux de traitement et examine le recours aux services de prise en charge du sevrage au Canada, y compris les épisodes de soins offerts dans le cadre de services spécialisés en milieu communautaire et hospitalier. Il fournit des renseignements pouvant guider les praticiens et les responsables des politiques dans leur prise de décisions relatives à la prise en charge du sevrage.},\n\tlanguage = {fr},\n\turldate = {2019-08-16},\n\tauthor = {{Centre canadien sur les dépendances et l’usage de substances}},\n\tkeywords = {Lignes directrices et prise en charge médicale},\n}\n\n
\n
\n\n\n
\n Ce rapport s’inscrit dans une série sur les indicateurs nationaux de traitement et examine le recours aux services de prise en charge du sevrage au Canada, y compris les épisodes de soins offerts dans le cadre de services spécialisés en milieu communautaire et hospitalier. Il fournit des renseignements pouvant guider les praticiens et les responsables des politiques dans leur prise de décisions relatives à la prise en charge du sevrage.\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n\n\n\n
\n\n\n \n\n \n \n \n \n\n
\n"}; document.write(bibbase_data.data);